<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of Paget disease of bone</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of Paget disease of bone</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of Paget disease of bone</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julia F Charles, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ethel Siris, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H16031870"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Paget disease of bone (PDB), also known historically as osteitis deformans, is a focal disorder of bone metabolism that occurs in the aging skeleton; it is characterized by an accelerated rate of bone remodeling, resulting in overgrowth of bone at single (monostotic PDB) or multiple (polyostotic PDB) sites and impaired integrity of affected bone. Commonly affected areas include the skull, spine, pelvis, and long bones of the lower extremity.</p><p>The majority of patients with PDB are asymptomatic. The diagnosis in such patients is usually made incidentally following a routine chemistry screen showing an elevated serum concentration of alkaline phosphatase of bone origin or an imaging study obtained for some other reason that shows pagetic changes in bone.</p><p>The two main clinical manifestations of Paget disease are pain due to the pagetic lesion in bone itself or from secondary consequences of bone overgrowth and deformities in affected areas, such as osteoarthritis or nerve impingement. Fractures, bone tumors, neurologic disease, and abnormalities in calcium and phosphate balance can also occur. In addition, because of the vascularity of pagetic bone, excessive bleeding may occur during orthopaedic surgery.</p><p>The pathogenesis, clinical manifestations, and diagnosis of PDB will be reviewed here. The treatment of this disorder is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5596.html" rel="external">"Treatment of Paget disease of bone"</a>.)</p><p class="headingAnchor" id="H16031877"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Paget disease of bone (PDB) is a fairly common finding in aging bone, with estimates ranging from 2.3 to 9 percent in older patients within affected populations [<a href="#rid1">1,2</a>]; it is often asymptomatic. Its onset is typically after age 55, with a slight predominance in men in some but not all studies. It is common in England, Scotland, Central Europe, and Greece, as well as in countries and cities settled by European immigrants, such as those in Australia, Canada, and the United States. Even within these countries, there are geographical clusters of disease [<a href="#rid1">1,3-7</a>]. Paget disease is rarely reported in the Scandinavian countries and Asia [<a href="#rid1">1,8-11</a>].</p><p>PDB is an ancient disease, claimed to be identified in a Neanderthal skull, with scattered reports of skeletal remains throughout history demonstrating this disorganized pattern of bone overgrowth [<a href="#rid12">12</a>]. The recognition of both geographic and familial clusters of the disease led to a search for both environmental and genetic causes [<a href="#rid3">3,13-16</a>]. (See <a class="local">'Pathogenesis'</a> below.)</p><p>The best initial estimates of prevalence came from two autopsy series in Europe performed during the mid-20<sup>th</sup> century on patients over the age of 40, in whom the prevalence was 3 to 3.7 percent [<a href="#rid12">12,17</a>]. In one series, only 7 of 24 patients recognized as having Paget disease had been diagnosed during their lifetimes (29 percent) [<a href="#rid17">17</a>]. The prevalence may rise to as high as 9 percent in older adults [<a href="#rid2">2</a>]. Over the last quarter-century, the prevalence of Paget disease appears to have diminished (except in regions of Italy) [<a href="#rid18">18</a>]. The extent of skeletal involvement is diminishing, and cases of symptomatic disease are less frequent [<a href="#rid15">15,19-25</a>].</p><p>Most of the estimates generated by epidemiological studies have relied upon the distribution of skeletal lesions, deriving prevalence estimates from reports of pagetic bone detected on screening abdominal radiographs (a "KUB" [kidneys, ureters, and bladder] view). Paget disease can affect almost any bone in the body but has a predilection for the skull, spine, pelvis, and long bones of the lower extremity. Thus, abdominal radiographs tend to capture the proximal femurs, pelvis, and lumbar spine (common sites of Paget disease) but miss patients with monostotic disease of the skull, upper spine, or distal extremity. Other epidemiological studies have relied on elevations of serum alkaline phosphatase (sAP) from bone as a marker for disease. However, a study of a population-based cohort from the Netherlands suggested that although sAP is a marker for PDB, the sAP level is normal in the majority of patients with Paget disease, particularly those with monostotic disease [<a href="#rid26">26</a>].</p><p>Several issues are likely to have led to an underestimation of the prevalence of Paget disease, including the facts that it is often asymptomatic, that screening abdominal radiographs are no longer routine with hospital admission, and that the diminished skeletal extent of Paget disease has made it less likely to be incidentally detected.</p><p class="headingAnchor" id="H16031884"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Paget disease of bone (PDB), which is characterized by an accelerated rate of bone remodeling resulting in overgrowth of bone at selected sites and impaired integrity of affected bone, is believed to be a disease of the osteoclast. Osteoclasts are the only cell known to resorb bone. Osteoclast differentiation requires pathways involving receptor activator for nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (MCSF), which are both necessary for osteoclast activation. RANKL binds to its receptor, RANK, on osteoclast precursors to promote osteoclast differentiation and activation via activation of nuclear factor kappa-B (NFkB)-dependent pathways. Osteoclast differentiation is inhibited by osteoprotegerin (OPG; a soluble decoy receptor for RANKL) and further modulated by cytokines and hormones. It is not known why some areas of bone are affected while others are not.</p><p>Evidence for the pivotal role of the osteoclast in PDB includes abnormalities in the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Osteoclast phenotype:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The osteoclasts in pagetic bone demonstrate an unusual appearance, with a disproportionate number of osteoclasts with too many nuclei.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intranuclear inclusion bodies may be noted in the nuclei of pagetic osteoclasts, but not in the nuclei of osteoblasts or in osteoclasts from unaffected bone of the same patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteoclast physiology:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Osteoclasts from patients with PDB show a hypersensitivity to vitamin D [<a href="#rid27">27-29</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antiresorptive agents used to treat PDB suppress osteoclastic activity and restore bone remodeling towards normal levels. Treatment with bisphosphonates can result in clinical remission of disease in many patients.</p><p></p><p>Both genetic and environmental causes are thought to contribute to the pathogenesis of the disease [<a href="#rid30">30</a>]. While it is clear that genetic mutations underlie susceptibility, a marked decrease in prevalence that has been shown in Britain and New Zealand also supports a role for environmental determinants [<a href="#rid20">20,22</a>]. However, there are no consistent correlates found between the occurrence of Paget disease and varied environmental exposures, including exposure to measles, dog ownership, urban versus rural living, heavy metals, milk ingestion, or family size.</p><p>PDB occurs in both familial and sporadic forms. A positive family history may be elicited in 12 to 40 percent of patients [<a href="#rid13">13,31</a>]. Persons with familial Paget disease may differ from those with sporadic Paget disease by having an earlier onset, more skeletal involvement, deformity, and fracture [<a href="#rid31">31-37</a>].</p><p class="headingAnchor" id="H16031891"><span class="h2">Genetic</span><span class="headingEndMark"> — </span>Significant evidence has accumulated that genetic factors influence the development of PDB [<a href="#rid38">38</a>]. The inheritance of familial PDB appears to be autosomal dominant with variable penetrance. Genome-wide association studies and candidate gene analyses have identified 15 genetic loci that are associated with PDB [<a href="#rid39">39-43</a>]. Most of these risk loci identify proteins known to affect bone physiology. Several directly affect RANK-RANKL pathway activity, such as the <em>TNFRSF11A </em>locus that encodes RANK.</p><p>The first and best-documented genetic association is with mutations in the ubiquitin-associated (UBA) domain of <em>SQSTM1</em>, which encodes the ubiquitin binding protein sequestosome-1. The <em>SQTSM1</em> P392L mutation<em> </em>was first identified in several French-Canadian kindreds with familial PDB. Study of familial cases from multiple countries has led to the identification of 28 different <em>SQSTM1 </em>mutations associated with PDB, of which P392L is by far the most common, occurring in up to 50 percent of familial PDB [<a href="#rid44">44,45</a>]. Germline <em>SQSTM1</em> mutations have also been identified in 2.6 to 16 percent of sporadic PDB [<a href="#rid46">46,47</a>], and somatic mutations have also been reported [<a href="#rid48">48,49</a>].</p><p>The presence of <em>SQSTM1</em> mutations, particularly truncation mutations, correlates with a more severe clinical phenotype [<a href="#rid50">50</a>]. However, of adults with <em>SQSTM1</em> mutations inherited from a parent with PDB, only 17 percent had evidence of PDB by bone scintigraphy, and their disease was attenuated compared with the affected parent [<a href="#rid51">51</a>]. This underscores the likely importance of gene-environment interactions for disease expression.</p><p>Many <em>SQSTM1</em> mutations enhance NFkB activation and thus osteoclast differentiation [<a href="#rid52">52</a>], while other mutations associated with PDB may affect the bone marrow microenvironment [<a href="#rid53">53</a>]. Neither mice transgenic for human P392L <em>SQSTM1</em> nor mice with the equivalent mutation at the endogenous locus develop PDB, although their osteoclasts have some characteristics of pagetic osteoclasts (eg, enhanced responsiveness to RANKL and tumor necrosis factor [TNF]) [<a href="#rid54">54</a>]. This provides further evidence that <em>SQSTM1</em> mutation alone is insufficient to promote disease.</p><p>Mutations in <em>ZNF687</em>, a zinc finger protein and possible transcriptional target of NFkB, were identified in an Italian family with severe PDB complicated by giant cell tumor [<a href="#rid55">55</a>]. As <em>SQSTM1</em> mutations are rare in Southern Italian PDB patients, who frequently have severe PDB, <em>ZNF687</em> was investigated in a cohort of 30 Southern Italian patients with polyostotic disease, and mutations in <em>ZNF687</em> were found in one-third [<a href="#rid56">56</a>]. Additionally, a common allelic variant in the locus for <em>OPTN</em>, encoding optineurin, an autophagy adaptor protein that appears to be involved in activation of the NFkB pathway, is strongly associated with PDB in multiple linkage studies. This variant was shown to increase <em>OPTN</em> expression and cause increased nuclear translocation of NFkB [<a href="#rid57">57</a>].</p><p>PDB is also observed in association with multisystem proteinopathy, a rare disease with a broad phenotypic spectrum, variably including PDB, inclusion body myopathy, motor neuron disease, parkinsonism, and frontotemporal dementia. This disease was first reported to be due to mutations in valosin-containing protein (<em>VCP</em>) [<a href="#rid58">58</a>]. Additional causative mutations have been reported in <em>SQSTM1</em> and several ribonucleic acid (RNA)-binding proteins [<a href="#rid59">59</a>]. The causative mutations are thought to alter the process of proteasomal degradation resulting in accumulation of undegraded proteins in stress granules and promoting tissue degeneration.</p><p>Three rare autosomal dominant skeletal dysplasias have been described that share some features with PDB (enlarged osteoclasts, skeletal enlargement, and deformity) but have additional manifestations that render them clinically distinct, including age of onset, hearing loss, and early loss of adult teeth. Early-onset Paget disease, familial expansile osteolysis, and expansile skeletal hyperphosphatasia are all caused by insertion mutations in the <em>TNFRSF11A</em> gene encoding RANKL and result in increased osteoclast activity.</p><p>A fourth disorder, called juvenile Paget disease (or hyperphosphatasia), is an autosomal recessive bone dysplasia with childhood onset that is unrelated to PDB in adults. Most reported cases are caused by a germline mutation in the gene for OPG, the decoy receptor for receptor activator for NFkB ligand (RANKL), leading to a deficiency of OPG. (See  <a class="medical medical_review" href="/z/d/html/2943.html" rel="external">"Osteogenesis imperfecta: An overview", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H16031898"><span class="h2">Viral</span><span class="headingEndMark"> — </span>Compared with the genetic findings, more limited information is available regarding potential environmental influences on PDB, including the possible role of viral infection. Findings of clusters of disease and observations that exposure to unvaccinated dogs, cats, or birds might be associated with a heightened risk of PDB led to the speculation that PDB might have a viral etiology [<a href="#rid60">60</a>]. The evidence for measles virus as an etiologic factor is substantial, and measles vaccination is postulated to explain the declining incidence of PDB. However, while measles remains a problem worldwide where vaccinations have not reached vulnerable populations [<a href="#rid5">5</a>], PDB has not been described as more prevalent in these populations.</p><p>The possibility that viral infection may play an important early role in the genetically susceptible host remains controversial and continues to be investigated. Initial observations pointed to intranuclear inclusions in pagetic osteoclasts resembling paramyxoviruses, with a structure similar to the nucleocapsids of measles. The expression of measles virus nucleocapsid protein (MVNP) in normal mouse osteoclasts promoted an osteoclast phenotype similar to pagetic osteoclasts [<a href="#rid61">61,62</a>] and caused a significant PDB phenotype in the presence of a <em>SQSTM1</em> mutation [<a href="#rid63">63</a>]. MVNP expression in osteoclasts has also been linked to increased osteoblast differentiation [<a href="#rid64">64</a>]. However, immunohistochemical and molecular approaches to confirming the presence of virus in bone biopsies from PDB patients have generated conflicting findings [<a href="#rid65">65-67</a>].</p><p class="headingAnchor" id="H3395682761"><span class="h2">Modifiable factors</span><span class="headingEndMark"> — </span>There are no known modifiable factors that contribute to PDB pathogenesis.</p><p class="headingAnchor" id="H22843862"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The osteoclasts in patients with Paget disease of bone (PDB) are bizarre in appearance, multinucleated, and excessive in number. Accelerated bone turnover results in the abnormal deposition of lamellar bone interspersed with woven bone. The bone is disorganized in appearance, with variably thickened trabeculae rimmed by numerous osteoblasts. The characteristic mosaic pattern is formed by randomly arrayed units of lamellar bone, which are delineated by irregular cement lines. The disorganized woven bone increases the bone volume, leading to many of the complications of the disease. The normal marrow is replaced by highly vascular stromal tissue  (<a class="graphic graphic_picture graphicRef64880" href="/z/d/graphic/64880.html" rel="external">picture 1</a>).</p><p class="headingAnchor" id="H16031905"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3081857661"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>The majority of patients with Paget disease of bone (PDB) are asymptomatic, although estimates vary widely [<a href="#rid68">68-70</a>]. When symptoms do arise, these are usually due to overgrowth, deformity, or pathologic fracture of the affected bone at a given skeletal location. Pain may arise either directly, from a pagetic lesion in bone, or from secondary causes, including osteoarthritis, nerve impingement, and tumor.</p><p>The two main clinical manifestations of Paget disease are pain, presumed to be due to the consequences of bone overgrowth, and deformities in affected areas. However, fractures, bone tumors, neurologic disease, and abnormalities in calcium and phosphate balance can also occur, though this is infrequent. Intrinsic cardiac disease due to PDB directly does not occur, but extensive polyostotic disease has rarely been associated with high-output heart failure as a secondary phenomenon. In addition, because of the vascularity of pagetic bone, excessive bleeding may occur during orthopaedic surgery.</p><p>Pain due to pagetic involvement of bone generally develops later in the course of disease and is typically a mild to moderate, deep, aching discomfort that persists through the day and at rest [<a href="#rid71">71</a>]. It may worsen with weightbearing and may be present at night. The etiology of the pain associated with the changes in bone is unclear. It may be due to periosteal changes caused by bone enlargement in association with hyperemia or microfractures in weightbearing bones.</p><p>The frequency of clinical findings depends upon the population studied (eg, registry versus clinical trial population, or the age of the study patients) and the methods by which data are obtained (eg, by patient or clinician questionnaires or by chart review) [<a href="#rid22">22,68,72-74</a>]; thus, estimates of different manifestations vary widely. The reason for this relates to the tendency of patients with Paget disease to be older adults and to assign their musculoskeletal complaints to this disorder of bone.</p><p>Symptoms and findings likely to be related to PDB among two cohorts of patients included [<a href="#rid68">68,73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Arthritis (40 to 50 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Pain (40 to 45 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Bone deformity (12 to 36 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Fracture (4 to 16 percent)</p><p></p><p>Other problems that may be attributed to PDB include [<a href="#rid22">22,68,72-74</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Radiculopathy due to nerve compression syndromes</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic back pain</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired functional status</p><p class="bulletIndent1"><span class="glyph">●</span>Hearing loss</p><p class="bulletIndent1"><span class="glyph">●</span>Headache</p><p class="bulletIndent1"><span class="glyph">●</span>Joint replacement surgery</p><p></p><p>Paget disease has a predilection for the skull, thoracolumbar spine, pelvis, and long bones of the lower extremities. It can be useful to think of the clinical manifestations of PDB in terms of these anatomical correlates:</p><p class="bulletIndent1"><span class="glyph">●</span>Skull – Involvement of the skull may lead to deformity, hearing loss (due to cochlear involvement), headache, dizziness and spinning sensations, and, rarely, neurological sequelae including hydrocephalus with instability of gait, dementia, or apathy from vascular steal due to heightened bone vascularity [<a href="#rid75">75</a>]. Enlargement of the skull, which can occur after many years of disease, may lead to a "tam-o-shanter" shape radiographically and may result in basilar invagination. Involvement of the mandible or maxillary bones may result in jaw deformity, malocclusion, and periodontal disease  (<a class="graphic graphic_diagnosticimage graphicRef71522" href="/z/d/graphic/71522.html" rel="external">image 1</a>) [<a href="#rid2">2,29</a>]. Angioid streaks can be found on ophthalmologic examination in up to 20 percent of patients with skull involvement as a component of active and more extensive Paget disease, compared with 15 percent of patients with active disease regardless of location and less than 2 percent of nonselected patients [<a href="#rid76">76,77</a>]. Wide, dilated scalp veins are commonly seen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spine and pelvis – Paget disease affecting the spine may lead to spinal stenosis at any level, bone pain, and nerve compression with attendant pain. A vascular steal may cause spinal cord dysfunction [<a href="#rid78">78</a>]. The abnormal bone may lead to a crippling compression fracture  (<a class="graphic graphic_diagnosticimage graphicRef51562" href="/z/d/graphic/51562.html" rel="external">image 2</a>). In the pelvis, Paget disease is often asymptomatic, unless it abuts a joint where softening of the bone may lead to pain, arthritis, and protrusio acetabuli  (<a class="graphic graphic_diagnosticimage graphicRef62514" href="/z/d/graphic/62514.html" rel="external">image 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long bones – Bowing deformities in the long bones and early arthritis of affected joints are common, with a heightened risk of fracture over the lifetime of the individual. The deformities are caused by enlarging and abnormally contoured bones, which result in bowing; the tibia and femur typically bow anteriorly and anterolaterally, respectively. Bowing may result in changes in gait and increased mechanical stresses that increase the likelihood of back and joint pain and of osteoarthritis. Patients with PDB have an increased likelihood of undergoing hip or knee replacement surgery for osteoarthritis compared with non-pagetic controls [<a href="#rid22">22</a>]. The skin overlying involved areas may feel warm due to increased blood flow.</p><p></p><p class="bulletIndent1">Traumatic and pathologic fractures are the most common complications of pagetic lesions in the long bones. Femoral fractures are more frequent than tibial fractures. The most common femoral site is in the area below the lesser trochanter. Fractures are usually transverse and perpendicular to the cortex. They can be either complete or incomplete (fissure fractures). Fissure fractures tend to occur along the convex surfaces of the curved bones but may progress to become complete fractures over time [<a href="#rid71">71,79</a>]. Fracture of pagetic bone may be associated with substantial blood loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyostotic disease – Polyostotic Paget disease may lead to metabolic disturbances, but these are rare with currently available therapies such as the nitrogen-containing bisphosphonates. Metabolic complications of Paget disease include high-output heart failure and hypercalciuria with a heightened frequency of kidney stones [<a href="#rid12">12</a>]. Casting or immobility may lead to profound osteopenia of the pagetic bone [<a href="#rid80">80</a>].</p><p></p><p class="headingAnchor" id="H21530713"><span class="h2">Bone tumors</span><span class="headingEndMark"> — </span>Patients with PDB are at increased risk for primary bone neoplasms, particularly osteosarcoma [<a href="#rid22">22,81</a>]. Osteosarcoma may arise in pagetic bone and presents with increased bone pain that is poorly responsive to medical therapy, local swelling, and, less often, a pathologic fracture  (<a class="graphic graphic_diagnosticimage graphicRef55541" href="/z/d/graphic/55541.html" rel="external">image 4</a>) [<a href="#rid68">68,82,83</a>]. Estimates of prevalence among patients with PDB range from 0.2 to 1 percent. An almost invariably fatal event, the osteosarcoma of PDB classically presents in those with extensive, longstanding skeletal disease. However, the epidemiology of this may be changing, and polyostotic, active disease may no longer predict those at risk for this disease [<a href="#rid84">84,85</a>]. The osteosarcoma affecting Paget patients probably has a distinct genetic signature from that of adolescent osteosarcomas [<a href="#rid82">82,84</a>]. (See  <a class="medical medical_review" href="/z/d/html/7722.html" rel="external">"Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis", section on 'Paget disease and other benign bone processes'</a>.)</p><p>Less commonly, giant cell tumors may arise in pagetic bone and are usually benign [<a href="#rid86">86</a>]. Similar to osteosarcomas, they may present with localized pain and swelling and typically occur in patients with polyostotic disease. Distinguishing between osteosarcoma and giant cell tumor is critical, as the former is generally fatal while the latter can be managed with medical therapy. While giant cell tumors typically arise in or adjacent to skeletal structures affected by PDB, they can occur in nonosseous tissues, in which case they are termed extraskeletal osteoclastomas. Giant cell tumors in PDB have several distinct characteristics when compared with non-PDB-associated disease, including a predilection for the axial skeleton (particularly the skull, facial bones, and pelvis), later age of onset, and frequency of multiple neoplasms [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/z/d/html/7731.html" rel="external">"Giant cell tumor of bone"</a>.)</p><p class="headingAnchor" id="H22843916"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Laboratory findings that result from increased bone turnover are typical of untreated disease in most patients. The following findings characterize this disorder:</p><p class="bulletIndent1"><span class="glyph">●</span>The serum alkaline phosphatase (sAP), like the bone-specific alkaline phosphatase (bAP), is frequently elevated in patients with PDB. The degree of elevation generally reflects the extent and activity of the disease, but this correlation is not as consistent as it was historically [<a href="#rid88">88-91</a>]. A normal or minimally elevated level may be seen in patients with monostotic disease and in some patients with polyostotic disease. [<a href="#rid92">92</a>]. As an example, a normal sAP can be seen in patients with an isolated pelvic lesion, with several vertebral bodies involved, or with end-stage sclerotic disease. By contrast, isolated Paget disease of the skull may produce very marked elevations in sAP [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other tests for markers of bone turnover that are often elevated with active disease include procollagen type I N-terminal propeptide (PINP), serum C-telopeptide (CTx), urinary N-telopeptide (NTx), and urinary hydroxyproline [<a href="#rid83">83,88-91</a>]. Serum CTx and urinary NTx reflect osteoclast activity (bone resorption), which is inhibited within days to weeks of treatment with a nitrogen-containing bisphosphonate. SAP, bAP, and PINP are measures of osteoblast function and return to normal gradually, sometimes over several months [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/z/d/html/2047.html" rel="external">"Bone physiology and biochemical markers of bone turnover"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium and phosphorus are normal in most patients. The finding of hypercalcemia in an ambulatory patient with PDB suggests the presence of a second disorder, such as primary hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/2029.html" rel="external">"Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H22844036"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Several imaging modalities, including plain radiography and bone scintigraphy, are useful in patients with suspected PDB, and findings on plain radiographs may be diagnostic, reflecting the abnormal bone turnover characteristic of disease. Additional imaging studies, including computed tomography (CT) and magnetic resonance imaging (MRI), may be useful in further evaluating unusual bone lesions or in other selected circumstances, particularly if malignancy is suspected.</p><p class="headingAnchor" id="H22844044"><span class="h3">Plain radiographs</span><span class="headingEndMark"> — </span>Plain films early in the disease course may show a predominantly osteolytic lesion. Over time, however, there is evidence of an osteoblast response, and the bone thickens and enlarges  (<a class="graphic graphic_diagnosticimage graphicRef75326" href="/z/d/graphic/75326.html" rel="external">image 5</a>). In late Paget disease, there may be dense bone by plain film, with little evidence of remodeling by biochemical parameters. Characteristic radiographic findings include [<a href="#rid94">94</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>"Osteoporosis circumscripta," which describes the osteolytic lesions that may be seen in the skull in early disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mixed lytic/sclerotic lesions, which gradually progress over time, resulting in thickening of cortical bone, heightened trabecular markings, and distortion and overgrowth of involved bone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progression of lesions originating in the subchondral bone and moving in one direction through the bone in a pattern sometimes described as "flame shaped," with cortical tunneling and trabecular thickening sometimes present  (<a class="graphic graphic_diagnosticimage graphicRef66075" href="/z/d/graphic/66075.html" rel="external">image 6</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pseudofractures, which may be seen as small fissures on the convex surface of long bones affected by bowing [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very infrequent identification of new bone lesions over time, although individual lesions evolve as noted above.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic involvement that results in protrusio acetabuli, which can give the pelvis a triangular appearance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iliopectineal line involvement, which is sometimes described as appearing in the shape of the number "3."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An ivory appearance of the affected spine in some patients. An affected vertebra is often enlarged in all three planes or may have the appearance of a picture frame. Additionally, vertebral enlargement may cause a loss of the normal lumbar lordosis and may accentuate the dorsal kyphosis.</p><p></p><p class="headingAnchor" id="H22844233"><span class="h3">Bone scintigraphy</span><span class="headingEndMark"> — </span>Increased uptake is seen focally at the sites of active pagetic bone lesions on radionuclide bone scanning and is more sensitive than plain radiography, particularly in early disease. The enhanced radionuclide uptake at pagetic lesions represents increased bone remodeling and blood flow  (<a class="graphic graphic_diagnosticimage graphicRef53321" href="/z/d/graphic/53321.html" rel="external">image 7</a>) [<a href="#rid71">71</a>]. The plain film  (<a class="graphic graphic_diagnosticimage graphicRef66075" href="/z/d/graphic/66075.html" rel="external">image 6</a>) demonstrates the radiographic correlates of this in the same patient (see <a class="local">'Plain radiographs'</a> above). Bone scanning can help establish the extent and distribution of bony lesions.</p><p>Findings on bone scans, however, are not specific. Sometimes evidence of Paget disease on bone scan antedates corresponding findings on plain radiographs.</p><p>The radionuclide uptake may decrease or normalize in the absence of significant disease activity (eg, patients with more longstanding or effectively treated disease). The degree of uptake may increase or decrease in patients with malignant transformation to osteosarcoma.</p><p class="headingAnchor" id="H27500927"><span class="h3">Other imaging modalities</span><span class="headingEndMark"> — </span>Other imaging technologies, such as CT or MRI, may be helpful in the evaluation of bone lesions if malignancy is a concern [<a href="#rid71">71,95</a>]. CT scanning may be useful for verifying whether the cortices of bone are intact and for defining the consequences of fractures or overgrowth of bone in the spine or skull. MRI may be helpful in distinguishing lytic or intermediate lesions of Paget disease from sarcoma [<a href="#rid96">96</a>]. Positron emission tomography (PET) scanning for malignancy may be "falsely positive," with increased uptake seen in active pagetic bone lesions [<a href="#rid97">97</a>]. The role of PET scanning in this setting is not well-defined. (See  <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">"Bone tumors: Diagnosis and biopsy techniques", section on 'Imaging'</a> and  <a class="medical medical_review" href="/z/d/html/7722.html" rel="external">"Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H16031919"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of Paget disease of bone (PDB) is primarily radiologic. In many patients, the serum alkaline phosphatase (sAP) is elevated, and additional tests of bone turnover are not required [<a href="#rid98">98</a>]. We diagnose PDB in patients with clinical or laboratory findings suggestive of disease upon the demonstration of characteristic radiographic changes at one or more affected skeletal sites.</p><p class="headingAnchor" id="H27501186"><span class="h2">Role of imaging</span><span class="headingEndMark"> — </span>Radiographs are usually diagnostic, showing the characteristic deformity of bone, with thickened cortices marked by tunneling, and accentuated trabeculae. Plain films obtained earlier in the course of illness may show a predominantly lytic lesion. Over time, however, there is evidence of an osteoblast response, and the bone thickens and enlarges  (<a class="graphic graphic_diagnosticimage graphicRef75326" href="/z/d/graphic/75326.html" rel="external">image 5</a>). In some cases of Paget disease, there may be dense bone by plain film, with little evidence of remodeling by biochemical parameters. (See <a class="local">'Plain radiographs'</a> above.)</p><p>A skeletal survey is not required, but a baseline radionuclide bone scan should be obtained in all patients with PDB to document the extent and locations of skeletal involvement  (<a class="graphic graphic_diagnosticimage graphicRef53321" href="/z/d/graphic/53321.html" rel="external">image 7</a>). A complete understanding of the locations of skeletal involvement is essential to determining indications for treatment. Note that the sites involved rarely change over a patient's lifetime. Findings on bone scans, however, are not specific, and plain film imaging of areas of increased uptake needs to be obtained to confirm the diagnosis. PDB-related changes on bone scan sometimes antedate corresponding findings on plain radiographs.</p><p>In a patient with known Paget disease, where bone scintigraphy is performed to assess the extent, distribution, and activity of disease, we obtain plain radiographs to confirm involvement at additional sites and evaluate for other bone lesions. In a patient in whom bone scintigraphy performed for other reasons is suggestive of Paget disease, then plain radiographic confirmation is also necessary.</p><p>We also obtain radiographs of affected sites to identify the musculoskeletal consequences of Paget disease, including fractures  (<a class="graphic graphic_diagnosticimage graphicRef51562" href="/z/d/graphic/51562.html" rel="external">image 2</a>), potential malignant lesions  (<a class="graphic graphic_diagnosticimage graphicRef55541" href="/z/d/graphic/55541.html" rel="external">image 4</a>), osteoarthritis, or other bone abnormalities  (<a class="graphic graphic_diagnosticimage graphicRef62514" href="/z/d/graphic/62514.html" rel="external">image 3</a>).</p><p>This approach is generally consistent with the clinical practice guidelines of the Endocrine Society and the 2019 Paget's Association guidelines [<a href="#rid99">99,100</a>].</p><p class="headingAnchor" id="H27501193"><span class="h2">Role of biochemical studies</span><span class="headingEndMark"> — </span>The sAP is usually adequate for assessment and monitoring of disease activity [<a href="#rid88">88-91</a>]. In patients with an elevated sAP, serum calcium and 25-hydroxy vitamin D levels should be obtained to exclude other causes of this elevation and in anticipation of treatment with a bisphosphonate.</p><p>Occasionally, bone-specific alkaline phosphatase (bAP) is measured in patients with liver disease or a characteristic bone lesion but who have normal sAP. Serum C-telopeptide (CTx) or procollagen type I N-terminal propeptide (PINP) are alternative markers that can be followed in patients with liver disease or in whom sAP is normal (see <a class="local">'Laboratory findings'</a> above). All three tests are commercially available.</p><p>In patients in whom sAP is not elevated with active disease documented by increased radionuclide uptake on bone scintigraphy, we obtain measurement of the bAP, serum CTx, and PINP to determine if there is a serum marker that can be followed for response to treatment. However, these additional markers may occasionally be normal, despite evidence of active disease on bone scintigraphy. If sAP is elevated, there is no clear utility to sending additional markers, in our experience.</p><p class="headingAnchor" id="H27508233"><span class="h2">Role of biopsy</span><span class="headingEndMark"> — </span>It is unusual that a bone biopsy is required to document the diagnosis of PDB, unless there is concern regarding the radiographic appearance of the lesion or possible metastatic disease (eg, a blastic lesion such as that seen in metastatic prostatic carcinoma or a lytic bone lesion in a patient with multiple myeloma). A biopsy of bone is required in the setting of monostotic lesions that do not show the characteristic radiographic findings of Paget disease. A biopsy may also be useful in a person suspected of Paget disease but in whom Paget disease would be unlikely, such as an individual from a country in which Paget disease is rare (eg, Korea) or a young adult. A biopsy is also indicated in the case of worsening pain or swelling at the site of known PDB to evaluate for osteosarcoma or giant cell tumor.</p><p class="headingAnchor" id="H1711070925"><span class="h2">Additional diagnostic considerations</span></p><p class="bulletIndent1"><span class="glyph">●</span>Osteoarthritis – In patients with known PDB and concurrent osteoarthritis, pain in or near a joint may be due to PDB close to the affected joint and/or the osteoarthritis. Improvement with treatment with an antiresorptive agent, such as a bisphosphonate, favors the PDB as the cause of pain. However, many older patients have pain from this as well as osteoarthritis of the joint, and while a bisphosphonate eases a component of their distress, attention to alleviating the pain from osteoarthritis is also necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperparathyroidism – Primary hyperparathyroidism can coexist in patients with PDB. Serum calcium is typically normal in PDB, so the presence of hypercalcemia in an ambulatory patient with PDB should raise the question of whether hyperparathyroidism is also present, and appropriate laboratory studies should be performed [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/z/d/html/2029.html" rel="external">"Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H21530746"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Paget disease of bone (PDB) occurs in an aging population that also has an increased prevalence of malignancy, osteoarthritis, and osteoporosis. Although the diagnosis of PDB is usually evident from radiographic findings, other conditions may also be present or have overlapping features.</p><p class="bulletIndent1"><span class="glyph">●</span>Metastatic disease – The mixed lytic/sclerotic appearance of PDB may make it difficult to radiographically distinguish metastatic malignancy in some patients. However, new lesions on bone scan generally do not occur in PDB over time. Thus, comparison with baseline plain radiographs and radionuclide bone scintigraphy can be helpful in determining whether a lesion requires further study. A biopsy may sometimes be required if imaging studies, including CT or MRI, are unable to distinguish these conditions with sufficient confidence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteomalacia – Osteomalacia, like PDB, may present with bone pain and an elevated serum alkaline phosphatase (sAP). The radiographic findings characteristic of PDB are absent. Pseudofractures may be present in osteomalacia (Looser's zones) but occur on the concave portion of the bone, unlike the fissure fractures in PDB that are present on the convex aspect. Osteomalacia is due to impaired mineralization of bone. The combined radiographic and laboratory features should allow these conditions to be readily distinguished. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia"</a> and  <a class="medical medical_review" href="/z/d/html/2040.html" rel="external">"Clinical manifestations, diagnosis, and treatment of osteomalacia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteosarcoma and giant cell tumors of bone – Osteosarcoma related to PDB typically presents with increasing localized bone pain and may be accompanied by soft tissue swelling in the affected area. Monitoring for the evolution of osteosarcoma arising in pagetic bone is not indicated. MRI can be helpful to define soft tissue anatomy and other changes of a malignancy such as cortical disruption by a mass. The diagnosis of osteosarcoma is made on bone biopsy. Giant cell tumors of bone are benign, but sometimes aggressive tumors that present with localized pain, swelling, and limitation of joint motion. In PDB, these tumors typically occur in the skull or pelvis of patients with polyostotic disease and can also arise in nonosseous tissues as extraskeletal osteoclastomas. Imaging studies and biopsy can help distinguish these lesions from each other and from PDB. (See  <a class="medical medical_review" href="/z/d/html/7722.html" rel="external">"Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">"Bone tumors: Diagnosis and biopsy techniques"</a> and  <a class="medical medical_review" href="/z/d/html/7731.html" rel="external">"Giant cell tumor of bone"</a>.)</p><p></p><p class="headingAnchor" id="H2174764756"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119746.html" rel="external">"Society guideline links: Paget disease of bone"</a>.)</p><p class="headingAnchor" id="H21530770"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87051.html" rel="external">"Patient education: Paget disease of bone (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/699.html" rel="external">"Patient education: Paget disease of bone (osteitis deformans) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21530754"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Paget disease of bone (PDB) is a fairly common finding in aging bone; it is often asymptomatic. Its onset is typically after age 55, with a slight predominance in men. It is common in England, Scotland, Central Europe, and Greece, as well as in countries and cities settled by European immigrants. Within these countries, there are geographical clusters of disease. Estimates of prevalence in some populations range from 3 percent in patients over 40 to up to 9 percent in older adults. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PDB is characterized by abnormalities of the osteoclast [<a href="#rid53">53</a>]; there are accelerated bone turnover and abnormal bone remodeling. Both genetic and environmental causes are thought to contribute to its pathogenesis. Inheritance appears to be autosomal dominant with variable penetrance, and multiple genetic loci have been associated with PDB. A pathogenic role for viral infection remains controversial. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Genetic'</a> above and <a class="local">'Viral'</a> above and <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of patients with PDB are asymptomatic. Symptoms are usually due to overgrowth of the affected bone. Pain may arise directly, from a pagetic lesion in bone, or from secondary causes, including osteoarthritis, fracture, nerve impingement, or, rarely, tumor. Paget disease has a predilection for the skull, thoracolumbar spine, pelvis, and long bones of the lower extremities. The common clinical manifestations include bone pain or chronic back pain, bone deformities, and arthritis, and depend upon the region involved. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteosarcoma is a rare, usually fatal complication of PDB, which typically presents in those with longstanding skeletal disease. Such patients may report increased bone pain that is poorly responsive to medical therapy, local swelling, and, less often, a pathologic fracture. Giant cell tumors may arise in pagetic bone and are usually benign. (See <a class="local">'Bone tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory findings, which reflect increased bone turnover and are typical of untreated disease, include elevated levels of serum alkaline phosphatase (sAP) and bone-specific alkaline phosphatase (bAP). The degree of elevation generally reflects the extent and activity of the disease, although this is not always the case. A normal or minimally elevated alkaline phosphatase may be seen in more limited disease. Serum calcium and phosphorus are normal in most patients. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plain radiographs reflect the abnormal bone turnover characteristic of disease. A predominantly osteolytic lesion may be seen early in disease. Over time, however, there is evidence of an osteoblast response, and the bone thickens and enlarges, with thickened cortices marked by tunneling and accentuated trabeculae at one or more affected skeletal sites. In late disease, there may be dense bone by plain film, with little evidence of remodeling by biochemical parameters. Increased uptake is seen focally at the sites of active pagetic bone lesions on radionuclide bone scanning. Bone scintigraphy is more sensitive than plain radiography, particularly in early disease. (See <a class="local">'Plain radiographs'</a> above and <a class="local">'Bone scintigraphy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of PDB in patients with clinical or laboratory findings suggestive of disease is confirmed by the demonstration of characteristic radiographic changes. In most patients, the sAP is elevated, and additional tests of bone turnover are not required. We obtain a baseline radionuclide bone scan to document the extent and locations of skeletal involvement; we perform radiographs of affected sites to identify impending fractures, potential malignant lesions, osteoarthritis, or other bone abnormalities. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Role of imaging'</a> above and <a class="local">'Role of biochemical studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PDB occurs in an aging population that also has an increased prevalence of malignancy, osteoarthritis, and osteoporosis. Although the diagnosis of PDB is usually evident from radiographic findings, other conditions may also be present or may have overlapping features. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2969071629"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Margaret Seton, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Altman RD, Bloch DA, Hochberg MC, Murphy WA. Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 2000; 15:461.</a></li><li class="breakAll">Siris E, Roodman GD. Paget Disease Section X. In: Primer on the Metabolic Bone Diseases, Favus MJ (Ed), ASBMR, Washington, DC 2003. p.495.</li><li><a class="nounderline abstract_t">Gardner MJ, Guyer PB, Barker DJ. Paget's disease of bone among British migrants to Australia. Br Med J 1978; 2:1436.</a></li><li><a class="nounderline abstract_t">Gómez Acotto C, Mautalen CA. European origin of patients with Paget's disease of bone in the Buenos Aires area. Eur J Epidemiol 2001; 17:409.</a></li><li><a class="nounderline abstract_t">Gennari L, Di Stefano M, Merlotti D, et al. Prevalence of Paget's disease of bone in Italy. J Bone Miner Res 2005; 20:1845.</a></li><li><a class="nounderline abstract_t">Barker DJ, Chamberlain AT, Guyer PB, Gardner MJ. Paget's disease of bone: the Lancashire focus. Br Med J 1980; 280:1105.</a></li><li><a class="nounderline abstract_t">Guyer PB, Chamberlain AT. Paget's disease of bone in two American cities. Br Med J 1980; 280:985.</a></li><li><a class="nounderline abstract_t">Falch JA. Paget's disease in Norway. Lancet 1979; 2:1022.</a></li><li><a class="nounderline abstract_t">Sridhar GR. Paget's disease in India: is it truly rare? Natl Med J India 1994; 7:101.</a></li><li><a class="nounderline abstract_t">Yip KM, Lee YL, Kumta SM, Lin J. The second case of Paget's disease (osteitis deformans) in a Chinese lady. Singapore Med J 1996; 37:665.</a></li><li><a class="nounderline abstract_t">Barker DJ. The epidemiology of Paget's disease. Metab Bone Dis Relat Res 1981; 3:231.</a></li><li><a class="nounderline abstract_t">DE DEUXCHAISNES CN, KRANE SM. PAGET'S DISEASE OF BONE: CLINICAL AND METABOLIC OBSERVATIONS. Medicine (Baltimore) 1964; 43:233.</a></li><li><a class="nounderline abstract_t">Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. J Bone Miner Res 1991; 6:495.</a></li><li><a class="nounderline abstract_t">Barker DJ, Clough PW, Guyer PB, Gardner MJ. Paget's disease of bone in 14 British towns. Br Med J 1977; 1:1181.</a></li><li><a class="nounderline abstract_t">Cooper C, Dennison E, Schafheutle K, et al. Epidemiology of Paget's disease of bone. Bone 1999; 24:3S.</a></li><li><a class="nounderline abstract_t">Detheridge FM, Guyer PB, Barker DJ. European distribution of Paget's disease of bone. Br Med J (Clin Res Ed) 1982; 285:1005.</a></li><li><a class="nounderline abstract_t">COLLINS DH. Paget's disease of bone; incidence and subclinical forms. Lancet 1956; 271:51.</a></li><li><a class="nounderline abstract_t">Rendina D, Gennari L, De Filippo G, et al. Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy. J Bone Miner Res 2006; 21:1828.</a></li><li><a class="nounderline abstract_t">Morales-Piga AA, Bachiller-Corral FJ, Abraira V, et al. Is clinical expressiveness of Paget's disease of bone decreasing? Bone 2002; 30:399.</a></li><li><a class="nounderline abstract_t">Doyle T, Gunn J, Anderson G, et al. Paget's disease in New Zealand: evidence for declining prevalence. Bone 2002; 31:616.</a></li><li><a class="nounderline abstract_t">Tiegs RD, Lohse CM, Wollan PC, Melton LJ. Long-term trends in the incidence of Paget's disease of bone. Bone 2000; 27:423.</a></li><li><a class="nounderline abstract_t">van Staa TP, Selby P, Leufkens HG, et al. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002; 17:465.</a></li><li><a class="nounderline abstract_t">Corral-Gudino L, García-Aparicio J, Sánchez-González MD, et al. Secular changes in Paget's disease: contrasting changes in the number of new referrals and in disease severity in two neighboring regions of Spain. Osteoporos Int 2013; 24:443.</a></li><li><a class="nounderline abstract_t">Mazières B, Coste J, Euller-Ziegler L, et al. Prevalence of pelvic Paget's disease of bone in France. Bone 2018; 107:143.</a></li><li><a class="nounderline abstract_t">Cook MJ, Pye SR, Lunt M, et al. Incidence of Paget's disease of bone in the UK: evidence of a continuing decline. Rheumatology (Oxford) 2021; 60:5668.</a></li><li><a class="nounderline abstract_t">Eekhoff ME, van der Klift M, Kroon HM, et al. Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam Study. J Bone Miner Res 2004; 19:566.</a></li><li><a class="nounderline abstract_t">Harvey L, Gray T, Beneton MN, et al. Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral aetiology. J Clin Pathol 1982; 35:771.</a></li><li><a class="nounderline abstract_t">Menaa C, Barsony J, Reddy SV, et al. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease. J Bone Miner Res 2000; 15:228.</a></li><li class="breakAll">Singer F, Krane S. Paget Disease of Bone. In: Metabolic Bone Diseases, Krane LV, Aa SM (Eds), WB Saunders, Philadelphia 1990. Vol 546.</li><li><a class="nounderline abstract_t">Cundy T, Reid IR. Paget's disease of bone. Clin Biochem 2012; 45:43.</a></li><li><a class="nounderline abstract_t">Seton M, Choi HK, Hansen MF, et al. Analysis of environmental factors in familial versus sporadic Paget's disease of bone--the New England Registry for Paget's Disease of Bone. J Bone Miner Res 2003; 18:1519.</a></li><li><a class="nounderline abstract_t">Barker DJ. The epidemiology of Paget's disease of bone. Br Med Bull 1984; 40:396.</a></li><li><a class="nounderline abstract_t">Barker DJ, Detheridge FM. Dogs and Paget's disease. Lancet 1985; 2:1245.</a></li><li><a class="nounderline abstract_t">Siris ES. Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions. Semin Arthritis Rheum 1994; 23:222.</a></li><li><a class="nounderline abstract_t">López-Abente G, Morales-Piga A, Elena-Ibáñez A, et al. Cattle, pets, and Paget's disease of bone. Epidemiology 1997; 8:247.</a></li><li><a class="nounderline abstract_t">Merlotti D, Gennari L, Galli B, et al. Characteristics and familial aggregation of Paget's disease of bone in Italy. J Bone Miner Res 2005; 20:1356.</a></li><li><a class="nounderline abstract_t">Morales-Piga AA, Rey-Rey JS, Corres-González J, et al. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 1995; 10:663.</a></li><li><a class="nounderline abstract_t">Alonso N, Calero-Paniagua I, Del Pino-Montes J. Clinical and Genetic Advances in Paget's Disease of Bone: a Review. Clin Rev Bone Miner Metab 2017; 15:37.</a></li><li><a class="nounderline abstract_t">Chung PY, Beyens G, Boonen S, et al. The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes. Hum Genet 2010; 128:615.</a></li><li><a class="nounderline abstract_t">Albagha OM, Visconti MR, Alonso N, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet 2010; 42:520.</a></li><li><a class="nounderline abstract_t">Albagha OM, Wani SE, Visconti MR, et al. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet 2011; 43:685.</a></li><li><a class="nounderline abstract_t">Beauregard M, Gagnon E, Guay-Bélanger S, et al. Identification of rare genetic variants in novel loci associated with Paget's disease of bone. Hum Genet 2014; 133:755.</a></li><li><a class="nounderline abstract_t">Usategui-Martín R, García-Aparicio J, Corral-Gudino L, et al. Polymorphisms in autophagy genes are associated with paget disease of bone. PLoS One 2015; 10:e0128984.</a></li><li><a class="nounderline abstract_t">Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; 70:1582.</a></li><li><a class="nounderline abstract_t">Morissette J, Laurin N, Brown JP. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. J Bone Miner Res 2006; 21 Suppl 2:P38.</a></li><li><a class="nounderline abstract_t">Falchetti A, Di Stefano M, Marini F, et al. Genetic epidemiology of Paget's disease of bone in italy: sequestosome1/p62 gene mutational test and haplotype analysis at 5q35 in a large representative series of sporadic and familial Italian cases of Paget's disease of bone. Calcif Tissue Int 2009; 84:20.</a></li><li><a class="nounderline abstract_t">Eekhoff EW, Karperien M, Houtsma D, et al. Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum 2004; 50:1650.</a></li><li><a class="nounderline abstract_t">Matthews BG, Naot D, Bava U, et al. Absence of somatic SQSTM1 mutations in Paget's disease of bone. J Clin Endocrinol Metab 2009; 94:691.</a></li><li><a class="nounderline abstract_t">Merchant A, Smielewska M, Patel N, et al. Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone. J Bone Miner Res 2009; 24:484.</a></li><li><a class="nounderline abstract_t">Rea SL, Walsh JP, Ward L, et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 2006; 21:1136.</a></li><li><a class="nounderline abstract_t">Cundy T, Rutland MD, Naot D, Bolland M. Evolution of Paget's disease of bone in adults inheriting SQSTM1 mutations. Clin Endocrinol (Oxf) 2015; 83:315.</a></li><li><a class="nounderline abstract_t">Goode A, Long JE, Shaw B, et al. Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function. Biochim Biophys Acta 2014; 1842:992.</a></li><li><a class="nounderline abstract_t">Hiruma Y, Kurihara N, Subler MA, et al. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 2008; 17:3708.</a></li><li><a class="nounderline abstract_t">Kurihara N, Hiruma Y, Zhou H, et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 2007; 117:133.</a></li><li><a class="nounderline abstract_t">Divisato G, Formicola D, Esposito T, et al. ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor. Am J Hum Genet 2016; 98:275.</a></li><li><a class="nounderline abstract_t">Divisato G, Scotto di Carlo F, Petrillo N, et al. ZNF687 mutations are frequently found in pagetic patients from South Italy: implication in the pathogenesis of Paget's disease of bone. Clin Genet 2018; 93:1240.</a></li><li><a class="nounderline abstract_t">Silva IAL, Conceição N, Gagnon É, et al. Molecular effect of an OPTN common variant associated to Paget's disease of bone. PLoS One 2018; 13:e0197543.</a></li><li><a class="nounderline abstract_t">Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36:377.</a></li><li><a class="nounderline abstract_t">Ralston SH, Taylor JP. Rare Inherited forms of Paget's Disease and Related Syndromes. Calcif Tissue Int 2019; 104:501.</a></li><li><a class="nounderline abstract_t">Khan SA, Brennan P, Newman J, et al. Paget's disease of bone and unvaccinated dogs. Bone 1996; 19:47.</a></li><li><a class="nounderline abstract_t">Reddy SV, Kurihara N, Menaa C, et al. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology 2001; 142:2898.</a></li><li><a class="nounderline abstract_t">Kurihara N, Reddy SV, Menaa C, et al. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest 2000; 105:607.</a></li><li><a class="nounderline abstract_t">Kurihara N, Hiruma Y, Yamana K, et al. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab 2011; 13:23.</a></li><li><a class="nounderline abstract_t">Teramachi J, Nagata Y, Mohammad K, et al. Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. J Clin Invest 2016; 126:1012.</a></li><li><a class="nounderline abstract_t">Mills BG, Singer FR, Weiner LP, Holst PA. Cell cultures from bone affected by Paget's disease. Arthritis Rheum 1980; 23:1115.</a></li><li><a class="nounderline abstract_t">Rebel A, Basle M, Pouplard A, et al. Towards a viral etiology for Paget's disease of bone. Metab Bone Dis Relat Res 1981; 3:235.</a></li><li><a class="nounderline abstract_t">Singer FR. Paget's disease of bone-genetic and environmental factors. Nat Rev Endocrinol 2015; 11:662.</a></li><li><a class="nounderline abstract_t">Wermers RA, Tiegs RD, Atkinson EJ, et al. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J Bone Miner Res 2008; 23:819.</a></li><li class="breakAll">Seton M. Paget's disease of bone. In: Rheumatology, 4th, Hochberg MC, Silman AJ, Smolen JS, et al. (Eds), Mosby (Elsevier), Philadelphia 2008. p.2003.</li><li><a class="nounderline abstract_t">Josse RG, Hanley DA, Kendler D, et al. Diagnosis and treatment of Paget's disease of bone. Clin Invest Med 2007; 30:E210.</a></li><li><a class="nounderline abstract_t">Whyte MP. Clinical practice. Paget's disease of bone. N Engl J Med 2006; 355:593.</a></li><li><a class="nounderline abstract_t">Falchetti A, Masi L, Brandi ML. Paget's disease of bone: there's more than the affected skeletal--a clinical review and suggestions for the clinical practice. Curr Opin Rheumatol 2010; 22:410.</a></li><li><a class="nounderline abstract_t">Seton M, Moses AM, Bode RK, Schwartz C. Paget's disease of bone: the skeletal distribution, complications and quality of life as perceived by patients. Bone 2011; 48:281.</a></li><li><a class="nounderline abstract_t">Langston AL, Campbell MK, Fraser WD, et al. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int 2007; 80:1.</a></li><li><a class="nounderline abstract_t">Devogelaer JP, Bergmann P, Body JJ, et al. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos Int 2008; 19:1109.</a></li><li><a class="nounderline abstract_t">Clarkson JG, Altman RD. Angioid streaks. Surv Ophthalmol 1982; 26:235.</a></li><li><a class="nounderline abstract_t">Dabbs TR, Skjodt K. Prevalence of angioid streaks and other ocular complications of Paget's disease of bone. Br J Ophthalmol 1990; 74:579.</a></li><li><a class="nounderline abstract_t">Yost JH, Spencer-Green G, Krant JD. Vascular steal mimicking compression myelopathy in Paget's disease of bone: rapid reversal with calcitonin and systemic steroids. J Rheumatol 1993; 20:1064.</a></li><li><a class="nounderline abstract_t">Redden JF, Dixon J, Vennart W, Hosking DJ. Management of fissure fractures in Paget's disease. Int Orthop 1981; 5:103.</a></li><li><a class="nounderline abstract_t">Wallace K, Haddad JG, Gannon FH, et al. Skeletal response to immobilization in Paget's disease of bone: a case report. Clin Orthop Relat Res 1996; :236.</a></li><li><a class="nounderline abstract_t">PRICE CH. The incidence of osteogenic sarcoma in South-West England and its relationship to Paget's disease of bone. J Bone Joint Surg Br 1962; 44-B:366.</a></li><li><a class="nounderline abstract_t">Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res 2006; 21 Suppl 2:P58.</a></li><li><a class="nounderline abstract_t">Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 2008; 372:155.</a></li><li><a class="nounderline abstract_t">Mankin HJ, Hornicek FJ. Paget's sarcoma: a historical and outcome review. Clin Orthop Relat Res 2005; 438:97.</a></li><li><a class="nounderline abstract_t">Deyrup AT, Montag AG, Inwards CY, et al. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch Pathol Lab Med 2007; 131:942.</a></li><li><a class="nounderline abstract_t">Rendina D, Mossetti G, Soscia E, et al. Giant cell tumor and Paget's disease of bone in one family: geographic clustering. Clin Orthop Relat Res 2004; :218.</a></li><li><a class="nounderline abstract_t">Rendina D, De Filippo G, Ralston SH, et al. Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone. J Bone Miner Res 2015; 30:257.</a></li><li><a class="nounderline abstract_t">Alvarez L, Guañabens N, Peris P, et al. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 2001; 29:447.</a></li><li><a class="nounderline abstract_t">Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004; 35:224.</a></li><li><a class="nounderline abstract_t">Peris P, Alvarez L, Vidal S, et al. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement. Calcif Tissue Int 2006; 79:22.</a></li><li><a class="nounderline abstract_t">Shankar S, Hosking DJ. Biochemical assessment of Paget's disease of bone. J Bone Miner Res 2006; 21 Suppl 2:P22.</a></li><li><a class="nounderline abstract_t">Harinck HI, Bijvoet OL, Vellenga CJ, et al. Relation between signs and symptoms in Paget's disease of bone. Q J Med 1986; 58:133.</a></li><li><a class="nounderline abstract_t">Harinck HI, Bijvoet OL, Blanksma HJ, Dahlinghaus-Nienhuys PJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop Relat Res 1987; :79.</a></li><li><a class="nounderline abstract_t">Griffiths HJ. Radiology of Paget's disease. Curr Opin Radiol 1992; 4:124.</a></li><li><a class="nounderline abstract_t">Sundaram M, Khanna G, El-Khoury GY. T1-weighted MR imaging for distinguishing large osteolysis of Paget's disease from sarcomatous degeneration. Skeletal Radiol 2001; 30:378.</a></li><li><a class="nounderline abstract_t">Sundaram M. Imaging of Paget's disease and fibrous dysplasia of bone. J Bone Miner Res 2006; 21 Suppl 2:P28.</a></li><li><a class="nounderline abstract_t">Spieth ME, Kasner DL, Manor WF. Positron emission tomography and Paget disease: hot is not necessarily malignant. Clin Nucl Med 2003; 28:773.</a></li><li><a class="nounderline abstract_t">Selby PL. Guidelines for the diagnosis and management of Paget's disease: a UK perspective. J Bone Miner Res 2006; 21 Suppl 2:P92.</a></li><li><a class="nounderline abstract_t">Singer FR, Bone HG 3rd, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:4408.</a></li><li><a class="nounderline abstract_t">Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. J Bone Miner Res 2019; 34:579.</a></li><li><a class="nounderline abstract_t">Brandi ML, Falchetti A. What is the relationship between Paget's disease of bone and hyperparathyroidism? J Bone Miner Res 2006; 21 Suppl 2:P69.</a></li></ol></div><div id="topicVersionRevision">Topic 5601 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10750560" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevalence of pelvic Paget's disease of bone in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10750560" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of pelvic Paget's disease of bone in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/719451" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Paget's disease of bone among British migrants to Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11855572" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : European origin of patients with Paget's disease of bone in the Buenos Aires area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16160742" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence of Paget's disease of bone in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7388425" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Paget's disease of bone: the Lancashire focus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7417771" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Paget's disease of bone in two American cities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/91758" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Paget's disease in Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8019388" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Paget's disease in India: is it truly rare?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9104073" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The second case of Paget's disease (osteitis deformans) in a Chinese lady.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7052246" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The epidemiology of Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14170787" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : PAGET'S DISEASE OF BONE: CLINICAL AND METABOLIC OBSERVATIONS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2068956" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Familial aggregation of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/861530" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Paget's disease of bone in 14 British towns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10321916" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Epidemiology of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6812718" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : European distribution of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13347083" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Paget's disease of bone; incidence and subclinical forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17002563" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856648" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Is clinical expressiveness of Paget's disease of bone decreasing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12477577" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Paget's disease in New Zealand: evidence for declining prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10962355" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term trends in the incidence of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11878305" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Incidence and natural history of Paget's disease of bone in England and Wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395312" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Secular changes in Paget's disease: contrasting changes in the number of new referrals and in disease severity in two neighboring regions of Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29175270" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevalence of pelvic Paget's disease of bone in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33742666" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence of Paget's disease of bone in the UK: evidence of a continuing decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15005843" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7096600" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral aetiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703924" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703924" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22024254" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12929942" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Analysis of environmental factors in familial versus sporadic Paget's disease of bone--the New England Registry for Paget's Disease of Bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6398113" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The epidemiology of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2866320" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dogs and Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8009230" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9115018" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cattle, pets, and Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007333" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Characteristics and familial aggregation of Paget's disease of bone in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7610939" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Frequency and characteristics of familial aggregation of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28255281" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical and Genetic Advances in Paget's Disease of Bone: a Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20839008" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20436471" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21623375" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Genome-wide association identifies three new susceptibility loci for Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24370779" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Identification of rare genetic variants in novel loci associated with Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26030385" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Polymorphisms in autophagy genes are associated with paget disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992264" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229007" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19067022" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Genetic epidemiology of Paget's disease of bone in italy: sequestosome1/p62 gene mutational test and haplotype analysis at 5q35 in a large representative series of sporadic and familial Italian cases of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15146436" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984666" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Absence of somatic SQSTM1 mutations in Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016598" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16813535" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25664955" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evolution of Paget's disease of bone in adults inheriting SQSTM1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24642144" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765443" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17187080" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26849110" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29493781" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : ZNF687 mutations are frequently found in pagetic patients from South Italy: implication in the pathogenesis of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29782529" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Molecular effect of an OPTN common variant associated to Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034582" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30756140" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rare Inherited forms of Paget's Disease and Related Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8830987" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Paget's disease of bone and unvaccinated dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11416009" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10712432" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21195346" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26878170" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6158956" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cell cultures from bone affected by Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6762481" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Towards a viral etiology for Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26284446" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Paget's disease of bone-genetic and environmental factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18269308" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Morbidity and mortality associated with Paget's disease of bone: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18269308" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Morbidity and mortality associated with Paget's disease of bone: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17892763" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Diagnosis and treatment of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899779" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical practice. Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20520551" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Paget's disease of bone: there's more than the affected skeletal--a clinical review and suggestions for the clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20858558" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Paget's disease of bone: the skeletal distribution, complications and quality of life as perceived by patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205328" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical determinants of quality of life in Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18504638" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7046115" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Angioid streaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2285679" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prevalence of angioid streaks and other ocular complications of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8350315" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Vascular steal mimicking compression myelopathy in Paget's disease of bone: rapid reversal with calcitonin and systemic steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7275410" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Management of fissure fractures in Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8653963" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Skeletal response to immobilization in Paget's disease of bone: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14038496" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The incidence of osteogenic sarcoma in South-West England and its relationship to Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229010" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Osteosarcoma in Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18620951" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pathogenesis and management of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131876" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Paget's sarcoma: a historical and outcome review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17550323" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123951" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Giant cell tumor and Paget's disease of bone in one family: geographic clustering.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25196811" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704497" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15207761" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868670" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229003" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Biochemical assessment of Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3714967" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Relation between signs and symptoms in Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2951049" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1292546" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Radiology of Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11499777" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : T1-weighted MR imaging for distinguishing large osteolysis of Paget's disease from sarcomatous degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229004" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Imaging of Paget's disease and fibrous dysplasia of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12973006" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Positron emission tomography and Paget disease: hot is not necessarily malignant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229017" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Guidelines for the diagnosis and management of Paget's disease: a UK perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406796" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Paget's disease of bone: an endocrine society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30803025" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229012" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : What is the relationship between Paget's disease of bone and hyperparathyroidism?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
